Bristol Myers Squibb Company Profile

What is the competitive landscape for BRISTOL MYERS SQUIBB, and what generic alternatives to BRISTOL MYERS SQUIBB drugs are available?

BRISTOL MYERS SQUIBB has seventy approved drugs.

There are thirteen US patents protecting BRISTOL MYERS SQUIBB drugs.

There are five hundred and ninety-six patent family members on BRISTOL MYERS SQUIBB drugs in fifty-one countries and one hundred and forty-three supplementary protection certificates in eighteen countries.

Summary for Bristol Myers Squibb

International Patents:	596
US Patents:	13
Tradenames:	60
Ingredients:	55
NDAs:	70

Drugs and US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-003	Dec 22, 1994		DISCN	Yes	No
Bristol Myers Squibb	VELOSEF	cephradine	TABLET;ORAL	050530-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	SUSTIVA	efavirenz	TABLET;ORAL	021360-001	Feb 1, 2002		DISCN	Yes	No
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-004	Dec 20, 2000		DISCN	Yes	No
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-003	Jun 28, 2006		RX	Yes	No
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	AB	RX	Yes	No	8,741,929
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986-002	Jun 28, 2006		RX	Yes	No	8,680,103*PED				Y

Expired US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	VIDEX	didanosine	TABLET, CHEWABLE;ORAL	020154-006	Oct 28, 1999	5,616,566*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-002	Sep 17, 1998	5,519,021*PED
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	9,101,621
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	9,155,730
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	9,056,120
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	6,315,720
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-002	Dec 22, 1994	4,338,317*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	25 mg		2010-07-12
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	600 mg		2009-04-09
	Nasal Spray	4 mg/spray		2016-07-15
	Tablets	2.5 mg and 5 mg		2016-12-28
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	30 mg		2005-06-01
	Tablets	80 mg and 140 mg		2011-06-16

International Patents for Bristol Myers Squibb Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2046331
Russian Federation	2406501
Denmark	3017811
Mexico	PA06001994
European Patent Office	2425836
Serbia	51444
Canada	2476983

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0584952	99C0004	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1169038	92146	Luxembourg		PRODUCT NAME: DASATINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
1427415	11C0042	France		PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110520
2782584	122021000080	Germany		PRODUCT NAME: ZUSAMMENSETZUNG, DIE SOWOHL ESTRADIOL (17SS-ESTRADIOL), GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON (EINSCHLIESSLICH IN FORM EINES HEMIHYDRATS), ALS AUCH PROGESTERON ENTHAELT; NAT. REGISTRATION NO/DATE: 2205034.00.00 20210924; FIRST REGISTRATION: BELGIEN BE582231 20210406
1427415	PA2011012	Lithuania		PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005 20110518
1353647	C300492	Netherlands		PRODUCT NAME: AZTREONAM, NIET IN EEN SAMENSTELLING MET ARGININE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN AZTREONAM, ANDERS DAN EEN ARGININEZOUT, IN HET BIJZONDER ALS AZTREONAMLYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb